晚期食管癌患者血清XRCC1基因多态性与铂类化疗疗效相关性的研究

目的：探讨XRCC1Arg399Gln（G＋A）基因多态性与晚期食管癌对以奥沙利铂为主的化疗敏感性的关系。方法：晚期食管癌患者87例（Ⅲ期41例,Ⅳ期46例）,采用改良FOLFOX方案化疗,46例Ⅳ期患者3个周期后进行临床疗效评价,87例患者统计至疾病进展时间（TTP）。应用TaqMan-MGB探针等位基因分型技术进行基因分型。结果：54.2%为A/A,34.5%为A/G,11.5%为G/G。Ⅳ期46例患者化疗后临床获益率（CR＋PR＋SD）为52.17%,A/A、G/A＋G/G在化疗敏感组与不敏感组中的分布具有统计学意义（χ2=6.213,P=0.023）。87例患者中位TTP 8个月,A/A基因型11个月,G/A＋G/G基因型4个月,两者比较差异有统计学意义（χ2=27.781,P〈0.01）。结论：XRCCl Arg399Gln基因多态性与晚期食管癌患者对奥沙利铂化疗的敏感性与生存时间相关。

Genetic polymorphism of XRCC 1 correlated with response to Oxaliplatin based treatment in advanced esophageal cancer

Objective：To examine the association between genetic polymorphisms of XRCC1 Arg399Gln（G→A）and response to Oxaliplatin-based chemotherapy for advanced esophageal cancer.Methods： Eighty seven advanced esophageal cancer patients（including 41 in stage Ⅲ were treated with Oxaliplatin-based chemotherapy,and clinical response of 46 patients in stage IV were evaluated after 3 cycles.All patients（87） were evaluated time to progress（TTP）.XRCCl genotypes were detected by TaqMan-MGB probe methods.Results： 54.2%were A/A genotype,11.5%were G/G genotype,and 34.5%were G/A genotype.The clinical benefit rate（CR＋PR＋SD） was 52.17%.Patients with A/A genotype showed distinctly preponderance compared to those with G/A＋G/G,between response group and un-response group（χ2=6.213,P=0.023）.The median TTP of all patients was 8 months.A/A genotype was 11 months;G/A and G/G was 4 months.There was a significant difference between them,χ2=27.781,P0.01.Conclusion： The XRCCl Arg399Gln genetic polymorphisms may be associated with clinical responses to Oxaliplatin-based chemotherapy and survival time in advanced esophageal cancer.